Readnour Robin Shane
SEC Form 4 insider trading activity
Readnour Robin Shane has filed 2 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Sep 8, 2026.
On the most recent filing, Readnour Robin Shane is listed as Director at AN2 Therapeutics, Inc. Inside the rolling window, Readnour Robin Shane reported no open-market purchases and 3 open-market sales totaling $310K in ANTX. The largest disclosed transaction in the window is a sale of 35,402 ANTX shares on Aug 17, 2026, worth $213K.
Companies traded
Other insiders at ANTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$310K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Readnour Robin Shane made?
Readnour Robin Shane has filed 2 SEC Form 4 filings (6 transaction rows) across 1 company since 2026.
Which companies does Readnour Robin Shane trade?
Readnour Robin Shane has filed SEC Form 4 disclosures for 1 company, including ANTX.
When was Readnour Robin Shane's most recent SEC Form 4 filing?
Readnour Robin Shane's most recent SEC Form 4 filing on Tracefour is dated Sep 8, 2026.
What is Readnour Robin Shane's total buy and sell value in the current window?
Inside the rolling retention window, Readnour Robin Shane bought $0 and sold $310K based on SEC Form 4 filings.
What was Readnour Robin Shane's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 35,402 ANTX shares on 2026-08-17, worth $213K, per SEC Form 4 filings.